Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 444

Sort by

Sort Order Select

Journal Articles

TET1 Modulates DNA Replication in Leukemia Cells Via a Catalytic-Independent Mechanism through Cooperating with KAT8

Hengyou Weng, PhD, Huilin Huang, PhD, He Huang, Zhaojin Yu, Paulina Siejka-Zielinska, Zhenhua Chen, PhD, Emily Prince, Chao Shen, PhD, Zejuan Li, MD, Chunxiao Song, Yingming Zhao, Jianjun Chen, PhD

Blood (2019) 134 (Supplement_1): 1249.

https://doi.org/10.1182/blood-2019-127321

Published: 2019

Journal Articles

Pre-Clinical Efficacy of Co-Treatment with KDM1A (LSD1) Inhibitor and Ruxolitinib or BET Inhibitor Against Post-MPN-sAML Blast Progenitor Cells

Warren Fiskus, BSc,PhD, Christopher Peter Mill, PhD BA, Vrajesh Karkhanis, PhD, Bernardo H Lara, Prithviraj Bose, MD, Lucia Masarova, Tapan M. Kadia, MD, Nancy Shao, Isean Bhalla, James V Maher, Joseph D. Khoury, MD, Sunil Sharma, MD, Taghi Manshouri, PhD, Srdan Verstovsek, MD PhD, Kapil N. Bhalla, MD

Blood (2019) 134 (Supplement_1): 1274.

https://doi.org/10.1182/blood-2019-130783

Published: 2019

Journal Articles

Adult Hematopoietic Stem and Progenitor Cell Maintenance Requires Histone Variant H3.3 Regulation By Hira

Rebecca Murdaugh, BS, Kevin Hoegenauer, Xiangguo Shi, PhD, Ayumi Kitano, Richard Chapple, PhD, Tianyuan Hu, PhD, Jonathan Tiessen, BS, Daisuke Nakada, PhD

Blood (2019) 134 (Supplement_1): 2473.

https://doi.org/10.1182/blood-2019-131358

Published: 2019

Journal Articles

Nascent Transcript and Single Cell Rnaseq Analysis Defines the Mechanism of Action of the LSD1 Inhibitor INCB059872 in Myeloid Leukemia

Gretchen Johnston, Haley E. Ramsey, PhDMSc, Kristy Stengel, PhD, Shilpa Sampathi, PhD, Pankaj Acharya, PhD, Maria Arrate, MSc, Matthew C. Stubbs, PhD, Timothy Burn, PhD, Scott Hiebert, PhD, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 2509.

https://doi.org/10.1182/blood-2019-130458

Published: 2019

Journal Articles

Mutant ASXL1 Disrupts Paraspeckle Formation through Aberrant Interaction with Nono in Hematopoietic Cells

Yamamoto Keita, MD, Susumu Goyama, MD PhD, Shuhei Asada, MD PhD, Takeshi Fujino, MD, Tomofusa Fukuyama, MD PhD, Yosuke Tanaka, MD, Ayana Kon, MD PhD, Yasuhito Nannya, MD PhD, Seishi Ogawa, MD PhD, Reina Onoguchi, PhD, Nobuyoshi Akimitsu, PhD, Toshio Kitamura, MD PhD

Blood (2019) 134 (Supplement_1): 2514.

https://doi.org/10.1182/blood-2019-125472

Published: 2019

Journal Articles

PRMT5 Is a Key Epigenetic Regulator That Promotes Transcriptional Activation in Mantle Cell Lymphoma By Regulating the Lysine Methyltransferase SETD7 and MLL1 Activity

JI Hyun Chung, PhD, Shelby Sloan, BS, Peggy Scherle, PhD, Kris Vaddi, PhD, Said Sif, PhD, Rosa Lapalombella, PhD, Robert A Baiocchi, MD PhD

Blood (2019) 134 (Supplement_1): 2777.

https://doi.org/10.1182/blood-2019-131020

Published: 2019

Journal Articles

SEL120 - a First-in-Class CDK8/19 Inhibitor As a Novel Option for the Treatment of Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome - Data from Preclinical Studies and Introduction to a Phase Ib Clinical Trial

Blood (2019) 134 (Supplement_1): 2651.

https://doi.org/10.1182/blood-2019-127835

Published: 2019

Journal Articles

A Phase Ib/II Study of the Histone Methyltransferase Inhibitor Pinometostat in Combination with Azacitidine in Patients with 11q23-Rearranged Acute Myeloid Leukemia

Kamal Menghrajani, MD, Sheng F Cai, MD PhD, Sean M. Devlin, PhD, Scott A. Armstrong, MD PhD, Richard Piekarz, MD PhD MS, BA, Michelle Rudek, PharmD, PhD, Martin S. Tallman, MD, Eytan M. Stein, MD

Blood (2019) 134 (Supplement_1): 2655.

https://doi.org/10.1182/blood-2019-121926

Published: 2019

Journal Articles

Novel Therapeutic Rationale for Targeting HDAC1 and PIM2 in Multiple Myeloma

Takeshi Harada, MD PhD, Asuka Oda, Hiroto Ohguchi, MD PhD, Yohann Grondin, PhD, Hirofumi Tenshin, DDS, PhD, Masahiro Hiasa, DDS, PhD, Jumpei Teramachi, Masahiro Oura, MD, Kimiko Sogabe, MD, Shiro Fujii, MD PhD, Shingen Nakamura, MD PhD, Hirokazu Miki, MD PhD, Kumiko Kagawa, MD PhD, Shuji Ozaki, MD PhD, Teru Hideshima, MD PhD, Kenneth C. Anderson, MD, Masahiro Abe, MD PhD

Blood (2019) 134 (Supplement_1): 3111.

https://doi.org/10.1182/blood-2019-127679

Published: 2019

Journal Articles

Anti-Tumor Effect of the EZH1/2 Dual Inhibitor Valemetostat Against Diffuse Large B-Cell Lymphoma Via Modulation of B-Cell Receptor Signaling and c-Myc Signaling Pathways

Yasuhiro Hama, PhD, Toshihiro Banjo, PhD, Daisuke Honma, PhD, Yoshimi Takata, Emi Nosaka, Machiko Shiroishi, Kenji Watanabe, Yuka Yamamoto, Tsuyoshi Hirata, Rika Nakano, Koichiro Inaki, PhD, Hiroki Goto, PhD, Yusuke Totoki, PhD, Miki Kataoka, Kyungtaek Lim, PhD, Chisa Wada, Eiji Kumazawa, PhD, Shinji Tsutsumi, PhD

Blood (2019) 134 (Supplement_1): 4642.

https://doi.org/10.1182/blood-2019-125436

Published: 2019

Journal Articles

A Novel and Potent EZH1/2 Dual Inhibitor HM97594 for the Treatment of Hematological Malignancies

Seung Hyun Jung, PhD, DongJin Hong, MS, SeoHee Kim, MS, Jiyoung Hwang, MS, Jooyun Byun, PhD, Miyoung Lee, MS, Kyounghwa Koo, PhD, Gunwoo Lee, MS, TaeHun Song, MS, SunYoung Lim, MS, Yu-Yon Kim, PhD, Hyunjin Park, PhD, Yesol Bak, PhD, Myoungsil Ko, MS, Sunyoung Jung, MS, Yuri Han, MS, YoungGil Ahn, PhD, YoungHoon Kim, PhD, KweeHyun Suh, PhD

Blood (2019) 134 (Supplement_1): 4648.

https://doi.org/10.1182/blood-2019-122982

Published: 2019

Journal Articles

A Combination Strategy Targeting Enhancer Plasticity Exerts Synergistic Lethality Against Beti-Resistant Leukemia Cells

Lei Guo, PhD, Jia Li, PhD, Hongxiang Zeng, PhD, Anna Guzman, Tingting Li, MD, Minjung Lee, MS, Yubin Zhou, PhD, Clifford Stephan, Peter J.A Davies, Margaret Goodell, PhD, Deqiang Sun, PhD, Mark A. Dawson, PhD MBBS, Yun Huang, PhD

Blood (2019) 134 (Supplement_1): 5053.

https://doi.org/10.1182/blood-2019-130586

Published: 2019

Journal Articles

This Is a Title in Title Case: A Combination of Low-Dose Decitabine and Chidamide Resulted in Synergistic Effects on the Proliferation and Apoptosis of Human Myeloid Leukemia Cell Lines

Fangfang Xu, PhD, Honggang Guo, MD, Mingyue Shi, MD, Siwei Liu, MD, Min Wei, MD, Kai Sun, MD, Yuqing Chen, MD

Blood (2019) 134 (Supplement_1): 5160.

https://doi.org/10.1182/blood-2019-128663

Published: 2019

Journal Articles

Single Cell Transcriptomic Analysis of the Histone H3 K27M Mutation in Pre-Leukemic Hematopoietic Stem Cells

Meaghan Boileau, BSc, Selin Jessa, BSc, Samantha Worme, BSc, Damien Faury, Nada Jabado, MD PhD, François Mercier, MD, Claudia Kleinman, PhD, Kolja Eppert, MSc, PhD

Blood (2019) 134 (Supplement_1): 3773.

https://doi.org/10.1182/blood-2019-123769

Published: 2019

Journal Articles

CDK8 Inhibitors Induce Transcriptional Reprogramming of AML Cells Associated with Differentiation

Milena Mazan, PhD, Marion Chapellier, PhD, Marcus Järås, PhD, Michal Mikula, MD PhD, Eliza Majewska, PhD, Katarzyna Wiklik, PhD, Michal Combik, PhD, Aniela Golas, PhD, Magdalena Masiejczyk, MSc, Elzbieta Fiedor, MSc, Federico Malusa, MSc, Przemyslaw Juszczynski, Prof., MD PhD, Magdalena Cybulska, DVM, Maciej Mikulski, PhD, Jerzy Ostrowski, Prof., MD PhD, Pawel Chrom, MD PhD, Krzysztof Brzózka, PhD, Tomasz Rzymski, PhD

Blood (2019) 134 (Supplement_1): 3774.

https://doi.org/10.1182/blood-2019-128073

Published: 2019

Journal Articles

Interrogating the Spatial Architecture of Human Bone Marrow Via Imaging Mass Cytometry

Karolyn A. Oetjen, MD, Diane E. Bender, PhD, Marianna B. Ruzinova, MD PhD, Stephen T. Oh, MD, Daniel C. Link, MD

Blood (2019) 134 (Supplement_1): 3728.

https://doi.org/10.1182/blood-2019-127460

Published: 2019

Journal Articles

S-Phase Progression of North American ATLL Cells Is Critically Regulated By the Proto-Oncogene BCL6 and Targetable By PARP Inhibition

B. Hilda Ye, PhD, Elaine Chung, PhD, Kith Pradhan, PhD, Ana Acuna-Villaorduna, MD, Yanhua Wang, MD PhD, Aditi Shastri, MD, Advaitha Madireddy, PhD, Amit Verma, MBBS, R.Alejandro Sica, MD, Murali Janakiram, MD MS

Blood (2019) 134 (Supplement_1): 3779.

https://doi.org/10.1182/blood-2019-131364

Published: 2019

Journal Articles

Targeting Salt-Inducible Kinase 3 As a Therapeutic Approach for Acute Myeloid Leukemia

Shan Lin, Yusuke Tarumoto, Jinhua Wang, PhD, Joseph Milazzo, Yali Xu, Nathanael Gray, Christopher Vakoc, Kimberly Stegmaier, MD

Blood (2019) 134 (Supplement_1): 3941.

https://doi.org/10.1182/blood-2019-125278

Published: 2019

Journal Articles

Aurora Kinase a/MDM2-Mediated SETD2 Loss of Function in Chronic Myeloid Leukemia Patients in Blast Crisis Can be Therapeutically Targeted Inducing Apoptotic Cell Death in a Caspase-Dependent Way

Blood (2019) 134 (Supplement_1): 4142.

https://doi.org/10.1182/blood-2019-126500

Published: 2019

Journal Articles

Strategy for Overcoming Crebbp and EP300 Mutations in Lymphoma: Development of First-in-Class HAT Activators

Yuxuan Liu, PhD, Jole Fiorito, PhD, Yulissa Gonzalez, Brian Estrella, PhD, Elisa Calcagno, PhD, Elisa Zuccarello, PhD, Howook Hwang, PhD, Barry Honig, PhD, Shixian Deng, PhD, Donald Landry, MD PhD, Owen A. O'Connor, MD PhD, Ottavio Arancio, PhD, Jennifer E Amengual, MD

Blood (2019) 134 (Supplement_1): 4068.

https://doi.org/10.1182/blood-2019-125983

Published: 2019

NARROW

TET1 Modulates DNA Replication in Leukemia Cells Via a Catalytic-Independent Mechanism through Cooperating with KAT8

Pre-Clinical Efficacy of Co-Treatment with KDM1A (LSD1) Inhibitor and Ruxolitinib or BET Inhibitor Against Post-MPN-sAML Blast Progenitor Cells

Adult Hematopoietic Stem and Progenitor Cell Maintenance Requires Histone Variant H3.3 Regulation By Hira

Nascent Transcript and Single Cell Rnaseq Analysis Defines the Mechanism of Action of the LSD1 Inhibitor INCB059872 in Myeloid Leukemia

Mutant ASXL1 Disrupts Paraspeckle Formation through Aberrant Interaction with Nono in Hematopoietic Cells

PRMT5 Is a Key Epigenetic Regulator That Promotes Transcriptional Activation in Mantle Cell Lymphoma By Regulating the Lysine Methyltransferase SETD7 and MLL1 Activity

SEL120 - a First-in-Class CDK8/19 Inhibitor As a Novel Option for the Treatment of Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome - Data from Preclinical Studies and Introduction to a Phase Ib Clinical Trial

A Phase Ib/II Study of the Histone Methyltransferase Inhibitor Pinometostat in Combination with Azacitidine in Patients with 11q23-Rearranged Acute Myeloid Leukemia

Novel Therapeutic Rationale for Targeting HDAC1 and PIM2 in Multiple Myeloma

Anti-Tumor Effect of the EZH1/2 Dual Inhibitor Valemetostat Against Diffuse Large B-Cell Lymphoma Via Modulation of B-Cell Receptor Signaling and c-Myc Signaling Pathways

A Novel and Potent EZH1/2 Dual Inhibitor HM97594 for the Treatment of Hematological Malignancies

A Combination Strategy Targeting Enhancer Plasticity Exerts Synergistic Lethality Against Beti-Resistant Leukemia Cells

This Is a Title in Title Case: A Combination of Low-Dose Decitabine and Chidamide Resulted in Synergistic Effects on the Proliferation and Apoptosis of Human Myeloid Leukemia Cell Lines

Single Cell Transcriptomic Analysis of the Histone H3 K27M Mutation in Pre-Leukemic Hematopoietic Stem Cells

CDK8 Inhibitors Induce Transcriptional Reprogramming of AML Cells Associated with Differentiation

Interrogating the Spatial Architecture of Human Bone Marrow Via Imaging Mass Cytometry

S-Phase Progression of North American ATLL Cells Is Critically Regulated By the Proto-Oncogene BCL6 and Targetable By PARP Inhibition

Targeting Salt-Inducible Kinase 3 As a Therapeutic Approach for Acute Myeloid Leukemia

Aurora Kinase a/MDM2-Mediated SETD2 Loss of Function in Chronic Myeloid Leukemia Patients in Blast Crisis Can be Therapeutically Targeted Inducing Apoptotic Cell Death in a Caspase-Dependent Way

Strategy for Overcoming Crebbp and EP300 Mutations in Lymphoma: Development of First-in-Class HAT Activators

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only